United Therapeutics Corporation (UTHR) Income Statement Analysis

See more : Stevia Corp. (STEV) Income Statement Analysis – Financial Results

Complete financial analysis of United Therapeutics Corporation (UTHR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of United Therapeutics Corporation, a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

American Metal & Technology, Inc. (AMGY) Income Statement Analysis – Financial Results
PT Madusari Murni Indah Tbk (MOLI.JK) Income Statement Analysis – Financial Results
Glunz & Jensen Holding A/S (GJ.CO) Income Statement Analysis – Financial Results
Venzee Technologies Inc. (VENZ.V) Income Statement Analysis – Financial Results
Cyber Apps World Inc. (CYAP) Income Statement Analysis – Financial Results

United Therapeutics Corporation (UTHR)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.unither.com

About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998
Revenue	2.33B	1.94B	1.69B	1.48B	1.45B	1.63B	1.73B	1.60B	1.47B	1.29B	1.12B	916.08M	743.18M	603.83M	369.85M	281.50M	210.94M	159.63M	115.92M	73.59M	53.34M	30.12M	5.73M	2.05M	400.00K	100.00K
Cost of Revenue	257.50M	146.70M	122.50M	108.10M	117.60M	198.70M	105.70M	72.70M	69.04M	125.88M	131.13M	119.30M	88.90M	73.47M	45.32M	30.07M	22.26M	17.03M	12.32M	8.25M	6.78M	5.46M	3.14M	1.71M	1.40M	0.00
Gross Profit	2.07B	1.79B	1.56B	1.38B	1.33B	1.43B	1.62B	1.53B	1.40B	1.16B	985.86M	796.78M	654.28M	530.37M	324.53M	251.43M	188.68M	142.60M	103.60M	65.34M	46.56M	24.66M	2.59M	343.47K	-1.00M	100.00K
Gross Profit Ratio	88.94%	92.42%	92.73%	92.71%	91.88%	87.79%	93.87%	95.45%	95.29%	90.23%	88.26%	86.98%	88.04%	87.83%	87.75%	89.32%	89.45%	89.33%	89.38%	88.79%	87.28%	81.89%	45.27%	16.76%	-250.00%	100.00%
Research & Development	408.00M	322.90M	540.10M	357.70M	1.18B	357.90M	264.60M	147.60M	245.10M	242.55M	299.35M	173.39M	180.02M	166.76M	122.19M	239.18M	83.35M	57.57M	36.05M	30.60M	35.42M	26.78M	32.59M	70.19M	30.70M	11.00M
General & Administrative	395.30M	416.20M	402.60M	369.00M	275.50M	206.70M	265.80M	232.20M	358.32M	299.29M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11.44M	16.94M	11.74M	5.00M	0.00
Selling & Marketing	81.80M	70.80M	64.40M	54.90M	60.70M	59.10M	64.30M	84.60M	94.30M	82.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.45M	3.38B	0.00	0.00	0.00
SG&A	477.10M	487.00M	467.00M	423.90M	336.20M	265.80M	330.10M	316.80M	452.61M	381.29M	394.01M	201.75M	156.48M	199.60M	176.34M	94.31M	99.03M	54.03M	24.66M	21.53M	22.67M	15.89M	16.94M	11.74M	5.00M	2.40M
Other Expenses	0.00	-40.20M	42.20M	49.30M	22.60M	-7.70M	13.20M	2.40M	157.00K	3.97M	635.00K	31.87M	156.48M	199.60M	176.34M	94.31M	99.03M	56.05M	24.66M	21.53M	22.67M	15.89M	0.00	-79.74K	-1.30M	2.40M
Operating Expenses	885.10M	809.90M	1.01B	781.60M	1.52B	623.70M	594.70M	464.40M	697.71M	623.84M	693.36M	375.13M	336.50M	366.36M	298.53M	333.49M	182.38M	113.62M	60.71M	52.13M	58.08M	42.67M	49.53M	81.84M	34.40M	13.40M
Cost & Expenses	1.14B	956.60M	1.13B	889.70M	1.64B	822.40M	700.40M	537.10M	766.75M	749.72M	824.49M	494.43M	425.40M	439.83M	343.85M	363.55M	204.64M	130.65M	73.02M	60.38M	64.87M	48.12M	52.67M	83.55M	35.80M	13.40M
Interest Income	162.70M	45.20M	16.70M	28.60M	44.20M	28.60M	10.90M	3.50M	0.00	0.00	3.83M	3.94M	3.45M	2.94M	5.15M	11.03M	13.60M	10.70M	5.36M	2.99M	2.44M	4.95M	10.02M	10.69M	0.00	0.00
Interest Expense	59.30M	32.40M	18.60M	23.50M	44.20M	13.90M	9.00M	3.90M	4.74M	17.59M	18.06M	16.64M	21.37M	19.71M	12.88M	16.00K	2.18M	482.00K	29.00K	4.00K	112.00K	117.00K	172.72K	120.04K	0.00	0.00
Depreciation & Amortization	53.20M	51.30M	49.90M	49.90M	45.90M	35.90M	31.00M	31.60M	32.92M	32.25M	31.26M	27.15M	20.54M	17.92M	11.39M	4.54M	957.00K	1.46M	2.41M	2.28M	2.33M	3.14M	3.51M	-79.74K	-1.30M	-500.00K
EBITDA	1.39B	1.04B	736.80M	646.30M	-74.90M	838.40M	1.05B	1.09B	1.08B	575.02M	323.76M	484.46M	341.02M	185.47M	43.04M	-67.75M	22.19M	28.98M	50.09M	17.83M	-9.20M	-14.87M	-43.42M	-81.58M	-36.66M	-13.80M
EBITDA Ratio	59.58%	50.85%	36.48%	45.27%	-8.34%	50.76%	60.17%	66.56%	47.70%	42.12%	26.59%	52.88%	43.21%	27.62%	8.38%	-25.31%	3.83%	19.59%	39.04%	20.98%	-17.60%	-15.25%	-754.18%	-3,752.55%	-9,200.00%	-13,800.00%
Operating Income	1.18B	979.70M	555.90M	593.60M	-187.60M	805.40M	814.90M	1.06B	699.02M	538.80M	292.50M	421.65M	317.78M	164.01M	26.00M	-82.06M	6.30M	28.98M	42.89M	13.21M	-11.53M	-18.00M	-46.94M	-81.50M	-35.40M	-13.30M
Operating Income Ratio	50.91%	50.60%	32.98%	40.02%	-12.95%	49.48%	47.23%	66.41%	47.69%	41.82%	26.19%	46.03%	42.76%	27.16%	7.03%	-29.15%	2.99%	18.16%	37.00%	17.95%	-21.61%	-59.77%	-818.93%	-3,977.08%	-8,850.00%	-13,300.00%
Total Other Income/Expenses	89.40M	-29.10M	38.00M	45.30M	22.60M	-46.50M	-45.40M	-1.50M	345.42M	-13.60M	-13.60M	19.03M	-18.67M	-16.17M	-7.23M	9.76M	10.28M	10.93M	4.63M	2.24M	1.56M	-5.65M	9.65M	-4.68M	63.50K	546.20K
Income Before Tax	1.27B	950.60M	593.90M	638.90M	-165.00M	758.90M	769.50M	1.06B	1.04B	525.18M	278.90M	440.67M	299.12M	147.84M	18.77M	-72.30M	16.58M	39.91M	47.52M	15.45M	-9.97M	-23.65M	-37.29M	-86.18M	-35.30M	-12.80M
Income Before Tax Ratio	54.75%	49.09%	35.24%	43.07%	-11.39%	46.62%	44.60%	66.31%	71.26%	40.76%	24.97%	48.10%	40.25%	24.48%	5.07%	-25.68%	7.86%	25.00%	41.00%	20.99%	-18.69%	-78.52%	-650.55%	-4,205.51%	-8,825.00%	-12,800.00%
Income Tax Expense	289.50M	223.30M	118.10M	124.10M	-60.50M	169.70M	351.60M	346.50M	392.80M	185.11M	104.34M	136.23M	81.87M	41.92M	-695.00K	-29.51M	-3.28M	-34.06M	-17.49M	-3.03M	-2.51M	5.44M	-9.65M	-5.89M	-1.90M	0.00
Net Income	984.80M	727.30M	475.80M	514.80M	-104.50M	589.20M	417.90M	713.70M	651.64M	340.07M	174.56M	304.44M	217.87M	105.92M	19.46M	-42.79M	19.86M	73.97M	65.02M	15.45M	-9.97M	-23.65M	-37.29M	-75.61M	-33.50M	-12.80M
Net Income Ratio	42.31%	37.56%	28.23%	34.71%	-7.21%	36.20%	24.22%	44.64%	44.46%	26.39%	15.63%	33.23%	29.32%	17.54%	5.26%	-15.20%	9.41%	46.33%	56.09%	20.99%	-18.69%	-78.52%	-650.55%	-3,689.55%	-8,375.00%	-12,800.00%
EPS	21.04	15.98	10.60	11.65	-2.39	13.54	9.50	16.29	14.17	7.06	3.49	5.84	3.81	1.89	0.37	-0.93	0.47	1.61	1.43	0.36	-0.24	-0.57	-0.92	-1.97	-1.26	-0.77
EPS Diluted	19.81	15.00	10.06	11.54	-2.39	13.39	9.31	15.25	12.72	6.28	3.28	5.71	3.67	1.78	0.35	-0.93	0.44	1.53	1.29	0.33	-0.24	-0.57	-0.92	-1.97	-1.26	-0.77
Weighted Avg Shares Out	46.80M	45.50M	44.90M	44.20M	43.80M	43.50M	44.00M	43.80M	46.00M	48.18M	50.08M	52.09M	57.16M	56.14M	53.31M	45.80M	42.45M	46.02M	45.65M	43.45M	42.27M	41.29M	40.57M	38.47M	26.69M	16.64M
Weighted Avg Shares Out (Dil)	49.70M	48.50M	47.30M	44.60M	43.80M	44.00M	44.90M	46.80M	51.22M	54.16M	53.23M	53.28M	59.40M	59.52M	56.13M	45.80M	44.90M	48.28M	50.41M	46.70M	42.27M	41.29M	40.57M	38.47M	26.69M	16.64M

The Bargain Hunter's Portfolio: 7 Smart Stock Buys for the Shrewd Investor

March 25, 2024investorplace.com

With so much attention paid to artificial intelligence and cryptocurrencies, the risk-on segment of the global markets has enjoyed tremendous upside, which subsequently makes the search for bargain stocks all the more important. While the heavy hitters can potentially still...

United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program

March 25, 2024businesswire.com

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its Board of Directors has authorized the company to purchase up to $1 billion of United Therapeutics' common stock. This...

Why Is United Therapeutics (UTHR) Up 8.9% Since Last Earnings Report?

March 22, 2024zacks.com

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

The 3 Most Undervalued Nasdaq Stocks to Buy in March 2024

March 13, 2024investorplace.com

Growth-oriented and patient investors love undervalued NASDAQ stocks to sink their teeth into. Despite current low prices, undervalued stocks present the opportunity to reap the benefits of future growth and sell at a significantly higher price.

Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making

March 5, 2024investorplace.com

The world of biotech stocks offers a unique blend of high risk and potentially high reward. Companies operating in this space are constantly pushing the boundaries, making them primed investment opportunities in 2024.

United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024

March 5, 2024businesswire.com

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company's operations during a fireside...

5 Small Drug Stocks to Buy From a Rebounding Industry

February 29, 2024zacks.com

Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.

United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference

February 27, 2024businesswire.com

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company's operations during a fireside...

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff

February 26, 2024investorplace.com

While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.